Remdesivir in Severe COVID-19 and Non-Invasive Ventilation: A Real-Life Experience.

Francesca SimioliCarmine NicolettaMaria Rosaria ValentinoMaria MartinoAnna AnnunziataNovella CarannantePierpaolo Di MiccoGiuseppe Fiorentino

Published in: Healthcare (Basel, Switzerland) (2021)

Results demonstrated that Remdesivir is associated with an improvement in clinical, laboratory and radiological parameters in patients with severe COVID-19 and showed an overall mortality of 13%. We conclude that, in this cohort, Remdesivir was a beneficial add-on therapy for severe COVID-19, especially in adults with moderate lung involvement at HRCT.

Keyphrases

coronavirus disease
sars cov
early onset
respiratory syndrome coronavirus
type diabetes
cardiovascular events
coronary artery disease
respiratory failure